PIK3CG and neoplasm: In the PIK3CA mutant model (HBCx-154), treatment with the three PI3K pathway inhibitors resulted in a significant inhibition of tumor growth (TGI= 80% for BAY-80-6946, p=0.006, 72% for PF-04691502 and AZD2014, p=0.02 and p=0.01, respectively).